Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Tiziana Life Sciences ( (TLSA) ).
On April 1, 2026, Tiziana Life Sciences reported positive preclinical data showing that nasal anti-CD3, including its intranasal foralumab candidate, can dampen microglial activation and reduce chronic neuroinflammation associated with aging, processes closely linked to cognitive decline. The study demonstrated that nasal anti-CD3 reversed key aspects of brain aging, enhanced hippocampal neurogenesis, and improved cognition in aging models, reinforcing the company’s mechanism-of-action thesis and supporting its broader development strategy in neurodegenerative and age-related cognitive disorders.
Company executives said these findings strengthen the scientific rationale for Tiziana’s ongoing clinical programs of intranasal foralumab in non-active secondary progressive multiple sclerosis and other neurologic indications, while encouraging expanded preclinical work in aging-related applications. The announcement underscores Tiziana’s bid to differentiate itself in the neuroinflammation field with a non-invasive, nasal immunotherapy platform that may offer safety, tolerability, and efficacy advantages over traditional intravenous delivery, potentially increasing its appeal to patients, clinicians, and investors if future clinical results are positive.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing immunotherapy treatments using alternative delivery technologies, notably intranasal administration. Its lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development and targets neuroinflammatory and neurodegenerative diseases such as non-active secondary progressive multiple sclerosis, MSA, ALS, and Alzheimer’s disease.
Average Trading Volume: 204,462
Technical Sentiment Signal: Sell
Current Market Cap: $139.1M
Learn more about TLSA stock on TipRanks’ Stock Analysis page.